A. Bardhan

Localized autosomal recessive epidermolysis bullosa simplex arising from a novel homozygous frameshift mutation in DST (BPAG1)

J. McGrath, L. Liu, D. Balacco, 2021, Clincal and Experimental Dermatology.

Epidermolysis Bullosa

J. McGrath, I. Chapple, C. Has, 2020, Braun-Falco´s Dermatology.

Toxic erythema as the first sign of COVID‐19 infection

A. Bardhan, M. Hunjan, L. Zuzarte, 2021, Clinical and experimental dermatology.

Successful use of rituximab, an anti‐CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa

G. Langman, V. Suresh, A. Heagerty, 2022, Clinical and experimental dermatology.

BG01: Safety and efficacy of oleogel‐S10 (birch triterpenes) for epidermolysis bullosa: results of a 12‐month interim analysis of the open‐label phase from the EASE study

D. Murrell, M. O’Sullivan, J. Kern, 2022, British Journal of Dermatology.

The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database *

J. McGrath, J. Mellerio, G. Petrof, 2021, The British journal of dermatology.

Epidermolysis bullosa

C. Has, J. Mellerio, L. Bruckner-Tuderman, 2020, Nature Reviews Disease Primers.

Genotype-phenotype correlation in Junctional Epidermolysis Bullosa: signposts to severity.

L. Ozoemena, D. Balacco, A. Bardhan, 2023, The Journal of investigative dermatology.